The EU has an European regulator and national value assessment authorities (e.g. HTAs and payers) with different remits, evidence requirements and approaches to uncertainty. Health technologies are increasingly being evaluated to determine their value and access. In this track we will explore how to respond to the challenges of determining the value of innovative and novel health technologies, different views of stakeholders and data requirements, and achieving patient-centric health systems (i.e. life cycle approach). The track will also explore different ways of anticipating and managing uncertainties across the lifecycle of a health technology, particularly involving Regulatory and Access landscapes. We invite abstracts containing multifunctional/ multistakeholder perspectives (at a minimum Regulatory and Access perspectives).

Who is This Track Designed For?

Professionals involved in patient access, market access, regulatory intelligence, health technology assessment, outcomes research, health economics, pricing and reimbursement, and regulatory strategy, from the industry as well as from governmental or public organizations and academics.